We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Cilostazol in Combination With L-Carnitine (ECLECTIC)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00822172
First Posted: January 14, 2009
Last Update Posted: May 22, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Otsuka Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Colorado Prevention Center
Results First Submitted: March 1, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Conditions: Peripheral Vascular Disease
Intermittent Claudication
Peripheral Arterial Disease
Interventions: Dietary Supplement: Levocarnitine tartrate
Drug: cilostazol

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The first participant was randomized on September 19th, 2008 and the last subject was randomized on May 7, 2010. Clinical study sites were a mixture of university/hospital settings, VA hospitals, professional research centers and medical clinics.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
The study included a cilostazol run in period. From the 164 participants who remained eligible at the end of the run in period, only 1 participant did not subsequently receive treatment. This was due to voluntary withdrawal by the participant.

Reporting Groups
  Description
Cilostazol + L-Carnitine

Levocarnitine tartrate : Capsule form, 1,002 mg (3 capsules) taken by mouth two times per day (morning and evening). L-carnitine will be taken from Day 0 to Day 180.

cilostazol : Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.

Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days.

Cilostazol + Placebo

cilostazol : Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.

Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days.


Participant Flow:   Overall Study
    Cilostazol + L-Carnitine   Cilostazol + Placebo
STARTED   80   83 
COMPLETED   65   64 
NOT COMPLETED   15   19 
Adverse Event                10                12 
Death                1                0 
Lost to Follow-up                3                1 
Withdrawal by Subject                1                4 
site closed                0                1 
Other                0                1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Cilostazol + L-Carnitine

Levocarnitine tartrate : Capsule form, 1,002 mg (3 capsules) taken by mouth two times per day (morning and evening). L-carnitine will be taken from Day 0 to Day 180.

cilostazol : Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.

Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days.

Cilostazol + Placebo

cilostazol : Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.

Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days.

Total Total of all reporting groups

Baseline Measures
   Cilostazol + L-Carnitine   Cilostazol + Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 80   83   163 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   43   27   70 
>=65 years   37   56   93 
Age 
[Units: Years]
Mean (Standard Deviation)
 65.8  (9.39)   67.3  (8.00)   66.5  (8.74) 
Gender 
[Units: Participants]
     
Female   14   16   30 
Male   66   67   133 
Region of Enrollment 
[Units: Participants]
     
United States   80   83   163 


  Outcome Measures

1.  Primary:   The Effect of Cilostazol Combined With L-carnitine on Change in Peak Walking Time (PWT) Compared to Cilostazol Alone From Baseline/Day 0 to Day 180 in Subjects With Peripheral Artery Disease (PAD) Limited by Intermittent Claudication (IC).   [ Time Frame: Day 0 to Day 180 ]

2.  Primary:   Safety of Combining Cilostazol With L-carnitine by Evaluating Laboratory Abnormalities and Adverse Events (AEs).   [ Time Frame: Day 0 to Day 210 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

3.  Secondary:   The Combination of Cilostazol and L-carnitine on PWT Compared to Cilostazol Alone From Baseline/Day 0 to Day 90 in Subjects With Peripheral Artery Disease (PAD) Limited by Intermittent Claudication (IC).   [ Time Frame: Day 0 to Day 90 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

4.  Secondary:   The Effect of the Combination of Cilostazol and L-carnitine on Claudication Onset Time (COT) and Quality of Life (QOL), as Measured Using the Walking Impairment Questionnaire (WIQ) and SF-36v2® at Days 90 and 180.   [ Time Frame: Day 0 to Days 90 and 180 ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: William Hiatt, MD, President
Organization: CPC Clinical Research
phone: 3038609900
e-mail: william.hiatt@cpcmed.org


Publications:
Hiatt WR. Management of Intermittent Claudication. Contemporary Diagnosis and management of Peripheral arterial Disease. 1 ed. Newtown: Handvbooks in Healthcare Co., Inc., 2004:51-9
Rizza v, Lorefice R, Rizza N et al. Pharmacokinetics of L-Carnitine in Human Subjects. In: Ferrari R, DiMauro S, Sherwood G, eds. L-Carnitine and its Role in Medicine: From Function to Therapy. 1 ed San Diego: Academic Press, Inc., 1992:63-77.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Colorado Prevention Center
ClinicalTrials.gov Identifier: NCT00822172     History of Changes
Other Study ID Numbers: CPC-08-01
First Submitted: January 13, 2009
First Posted: January 14, 2009
Results First Submitted: March 1, 2013
Results First Posted: May 22, 2013
Last Update Posted: May 22, 2013



To Top